Naomi Aronson, PhD, is the Executive Director of Clinical Evaluation, Innovation, and Policy, Blue Cross & Blue Shield Association, and a member of the EXCITE International Advisory Council and the ISC.
Dr. Naomi Aronson leads BCBSA clinical effectiveness and policy engagement with government, regulatory agencies and policy consortia. Her areas of leadership include comparative effectiveness, patient centered research, safety surveillance, regulatory science and methodological standards.
Previously, Dr. Aronson led the development of the BCBSA Technology Evaluation Center (TEC), now Evidence StreetTM (ES), as a nationally recognized technology assessment program and an Evidence- based Practice Center (EPC) of the Agency for Healthcare Research and Quality (AHRQ).
She is a member of the Methodology Committee of the Patient-Centered Outcomes Research Institute (PCORI), the Health Technology Assessment International Health Policy Forum, the National Academy of Medicine Genomics Roundtable, the National Business Group on Health Committee on Evidence- Based Benefit Design, the New Drug Development Paradigms (NEWDIGS) initiative of the MIT Center for Biomedical Innovation, Steering Committee of the Quality Assurance Pilot for Cancer CDx, Member Clinical Trials Transformation Initiative (CTTI) Real World Evidence (RWE) Project Team, and the Medical Device Innovation Consortium (MDIC) National Evaluation System for Health Technology (NEST) Governing Committee.
Executive Director, Clinical Evaluation, Innovation, and Policy, Blue Cross & Blue Shield Association